[Efficacy of intravenous ceftazidime in childhood infections].

Ceftazidime, a beta-lactamase resistant cephalosporin, was administered intravenously to 33 patients with various infections. The age range was between 3 days and 15 years and substantial underlying disease was present in 90% of the patients and 72% had malignancy. Seventeen (51.5%) were in critical condition and twenty had granulocytopenia. Clinical and microbiological results were evaluated and overall clinical response was 88%. No major adverse effects were encountered. Ceftazidime was an effective and safe therapy for serious infections and neutropenic patients.